India Pharma Outlook Team | Tuesday, 04 August 2026
Retatrutide Early Access has started for a limited group of patients before its expected FDA approval. Eli Lilly has launched an expanded access program for eligible adults with severe obesity.
The move comes as the company prepares regulatory submissions for its next-generation obesity drug. The decision reflects growing demand for advanced obesity treatment options for patients with serious health conditions.
The company said the program will support adults who cannot join clinical trials. These patients must have refractory obesity and at least two obesity-related health conditions. Lilly plans to submit Retatrutide for U.S. regulatory approval in early 2027.
The early access program is available only through treating physicians. Doctors must apply on behalf of eligible patients. Lilly will review each request before approving treatment.
Retatrutide will be offered through an expanded access, or compassionate use, program. Such programs help patients with serious diseases receive investigational medicines before formal approval.
To qualify, patients must:
The company said the program is designed for patients with limited treatment options. It does not replace ongoing clinical studies.
Lilly will continue collecting data from its late-stage clinical trials while evaluating requests under the expanded access program.
Also Read: Driving Vaccine Adoption Beyond Pediatric Immunization in India
Retatrutide is different from current obesity medicines because it targets three hormone pathways.
The investigational therapy activates:
Most currently approved obesity medicines target one or two hormone receptors. Lilly's approved medicine, Zepbound, works on GLP-1 and GIP receptors. Retatrutide adds glucagon receptor activity, aiming to deliver greater weight loss.
This triple-action approach has made the drug one of the most closely watched obesity therapies in development.
Clinical studies have produced encouraging results for Retatrutide. In an 80-week Phase III study involving adults with severe obesity and cardiovascular disease, patients receiving the highest dose achieved an average weight loss of 22.6%.
Earlier studies also showed weight reductions exceeding 28% in some patient groups. These results have strengthened expectations that Retatrutide could become one of the most effective obesity medicines after regulatory approval.
The expanded access program marks an important milestone for Lilly's obesity portfolio. It also offers hope to patients with severe obesity who have exhausted available treatment options. If approved, Retatrutide could further reshape the rapidly growing obesity treatment market.
